All good points golf ... "feels" like a high stakes game of chicken to me, with BP. The further down the path we go, with more good news progressively arriving is a very good thing, and confidence is much higher now, and the further the acquisition price goes up. I feel like we are back in the driver seat, now that a critical first domino has at least tilted, if not fallen, with more to come as you pointed out. This puts increasing upward purchase value pressure on interested and competing BP's, and RVX owners/investors have to decide when to take a sure thing and an acceptable ROI/value ... 

I do like the star factory concept, if RVX doesn't receive a global offer (full buy out vs just apabetalone) that it just can't refuse. And the price for the full star factory goes up also, as apabetalone/epigenetics gets closer and closer (and achieves) regulatory validation.

In October 2019 I might have been begrudgingly happy selling RVX for $1b and 4 times my ROI on my original investment ... and I would have lunged head first without a helmet or mouth piece at $4b (16 x's ROI) per Don's reported anecdotal AGM value.

Today I believe it is worth more, probably much more. Tomorrow (later this year), probably even more. 

Here for the longgggg ride ... so yes sir, patience is a virtue.